[go: up one dir, main page]

DE69833645D1 - Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen - Google Patents

Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen

Info

Publication number
DE69833645D1
DE69833645D1 DE69833645T DE69833645T DE69833645D1 DE 69833645 D1 DE69833645 D1 DE 69833645D1 DE 69833645 T DE69833645 T DE 69833645T DE 69833645 T DE69833645 T DE 69833645T DE 69833645 D1 DE69833645 D1 DE 69833645D1
Authority
DE
Germany
Prior art keywords
mirtazapine
antipsychotics
prophylaxis
treatment
psychotic disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833645T
Other languages
English (en)
Other versions
DE69833645T2 (de
Inventor
Louis Broekkamp
Henricus Berendsen
Martin Pinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of DE69833645D1 publication Critical patent/DE69833645D1/de
Application granted granted Critical
Publication of DE69833645T2 publication Critical patent/DE69833645T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69833645T 1997-03-27 1998-03-25 Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen Expired - Lifetime DE69833645T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP97200881 1997-03-27
EP97200881 1997-03-27
EP97202785 1997-09-11
EP97202785 1997-09-11
PCT/EP1998/001920 WO1998043646A1 (en) 1997-03-27 1998-03-25 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders

Publications (2)

Publication Number Publication Date
DE69833645D1 true DE69833645D1 (de) 2006-04-27
DE69833645T2 DE69833645T2 (de) 2006-08-24

Family

ID=26146283

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833645T Expired - Lifetime DE69833645T2 (de) 1997-03-27 1998-03-25 Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen

Country Status (25)

Country Link
EP (1) EP0969845B1 (de)
JP (2) JP4377456B2 (de)
KR (1) KR100577865B1 (de)
CN (1) CN1226036C (de)
AR (1) AR012193A1 (de)
AT (1) ATE318604T1 (de)
AU (1) AU726194B2 (de)
BR (1) BR9808077A (de)
CA (1) CA2284551C (de)
CZ (1) CZ298105B6 (de)
DE (1) DE69833645T2 (de)
DK (1) DK0969845T3 (de)
ES (1) ES2259207T3 (de)
HK (1) HK1023293A1 (de)
HU (1) HUP0002742A3 (de)
ID (1) ID22283A (de)
IL (1) IL123716A (de)
NO (1) NO994673L (de)
NZ (1) NZ337618A (de)
PL (1) PL191449B1 (de)
PT (1) PT969845E (de)
RU (1) RU2222330C2 (de)
TR (1) TR199902334T2 (de)
TW (1) TW587938B (de)
WO (1) WO1998043646A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
US6350773B1 (en) 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
HUP0204050A3 (en) 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
DE60219761T2 (de) 2001-02-06 2008-01-17 Astrazeneca Ab Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
EP1795199A3 (de) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapin für die Behandlung von Substanzabhängigkeit oder Substanzmissbrauch
KR101409724B1 (ko) 2003-10-29 2014-06-19 와이어쓰 엘엘씨 아플린도어 및 이의 유도체를 포함하는 서방성 약제학적조성물
EP1547650A1 (de) * 2003-12-02 2005-06-29 B & B Beheer NV Verwendung von D4 und 5-HT2A Antagonisten, inverse Agonisten order partielle Agonisten
PL1541197T3 (pl) * 2003-12-02 2009-10-30 Pharmaneuroboost N V Zastosowanie pipamperonu i SNDRI, SNRI lub SSRI do leczenia zaburzeń nastroju lub zaburzeń lękowych z niepokojem
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005117916A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
KR101390012B1 (ko) * 2006-06-09 2014-04-29 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 테이프 제제
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
DE102012011839B4 (de) 2012-06-14 2018-03-22 Norbert Müller Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen
RU2509560C1 (ru) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2410821A1 (de) * 1974-03-07 1975-09-18 Hoechst Ag Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
DE69005992T2 (de) * 1989-12-06 1994-05-05 Akzo Nv Psychotropische Wirkstoffe enthaltende stabilisierte Lösungen.
ZA935078B (en) * 1992-07-15 1994-02-07 Nicolaas Johannes Jaco Loetter Pharmaceutical composition
ATE188375T1 (de) * 1992-11-17 2000-01-15 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
JPH07242669A (ja) * 1994-03-07 1995-09-19 Akikazu Ogawa 四環系とブチロフェノン誘導体を化学結合した化合物

Also Published As

Publication number Publication date
ID22283A (id) 1999-09-30
KR100577865B1 (ko) 2006-05-10
HK1023293A1 (en) 2000-09-08
DK0969845T3 (da) 2006-06-19
PL335890A1 (en) 2000-05-22
AR012193A1 (es) 2000-09-27
NO994673L (no) 1999-11-17
PT969845E (pt) 2006-05-31
IL123716A0 (en) 1998-12-06
JP2009280596A (ja) 2009-12-03
KR20010005677A (ko) 2001-01-15
AU7213998A (en) 1998-10-22
PL191449B1 (pl) 2006-05-31
CA2284551C (en) 2007-06-12
TW587938B (en) 2004-05-21
NO994673D0 (no) 1999-09-24
CZ343199A3 (cs) 2000-04-12
NZ337618A (en) 2000-06-23
EP0969845B1 (de) 2006-03-01
IL123716A (en) 2001-03-19
EP0969845A1 (de) 2000-01-12
TR199902334T2 (xx) 2000-01-21
RU2222330C2 (ru) 2004-01-27
ES2259207T3 (es) 2006-09-16
JP2001521497A (ja) 2001-11-06
HUP0002742A2 (hu) 2001-05-28
CZ298105B6 (cs) 2007-06-27
DE69833645T2 (de) 2006-08-24
AU726194B2 (en) 2000-11-02
BR9808077A (pt) 2000-03-08
JP5023315B2 (ja) 2012-09-12
WO1998043646A1 (en) 1998-10-08
HUP0002742A3 (en) 2003-03-28
JP4377456B2 (ja) 2009-12-02
CA2284551A1 (en) 1998-10-08
CN1226036C (zh) 2005-11-09
CN1251526A (zh) 2000-04-26
ATE318604T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
DE69833645D1 (de) Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE251903T1 (de) Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
DE69704877D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
DE60143061D1 (de) Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
EP1043983A4 (de) Tetracycline und/oder tetracyclinderivate zur behandlung und prophylaxe von cerebrovascularen krankheiten des nervensystems
EP1117395A4 (de) Verbindungen zur behandlung von östrogenabhängigen erkrankungen und deren herstellungs und verwendungsmethoden
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE69625883D1 (de) Zusammensetzung zur Reinigung und/oder Desinfektion von medizinischen Geräten
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

R082 Change of representative

Ref document number: 969845

Country of ref document: EP

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE